Welcome to HTI Consultancy,
where we help you to gain insights on the position of your health innovation in comparison to the current health lanscape.
I’m Katharina, a health economics expert specialised in health innovations.
I use health economic modelling to quantify how much value your technology brings compared to current care—both in terms of health gains for patients and costs for the healthcare system. By applying clear health economic principles, I help you identify the strengths and weaknesses of your innovation, so you can make informed decisions about development, positioning, and reimbursement.
“Does your technology perform better than that of your competitors?
That’s a big plus.
But what about the costs? Are they higher — and if so, how much better does your health technology need to perform to offset those extra costs?”
If you do not know the answer yet, let’s get together, and find out!
HTI can help you with questions on…
Pricing strategies
What is the potential monetary value of my technology given its expected health benefits?
What is the potential maximum benefit I could achieve with my health technology in its field of application?
Where in the care pathway should I position my health technology?
Reimbursement
I was asked to provide a budget impact analysis/ cost-effectiveness analysis for my health technology. What do I need to do? How can I provide this?
What health economics data do I need to collect in my study for reimbursement?
What do I need to do to get my technology reimbursed?
Investor readiness
We conducted a study and want to know whether the new technology could be reimbursed.
Does my health innovation have a potential monetary benefit? And if so, what is the magnitude?
Do you have a different question regarding your health technology? Reach out to find out what is needed to answer your questions.
In a clinical trial, our client evaluated how their digital health innovation improved the health of cancer survivors. Alongside clinical outcomes, they systematically collected data on healthcare use—such as specialist and GP visits, and medication consumption.
We translated these data into robust cost estimates at the population level, comparing the innovation to current care. This analysis gave the client clear insight into the potential cost impact of their solution and directly informed their reimbursement strategy and investment decisions—turning trial results into a concrete business and market access plan.
A client wanted to understand the monetary value of their new health innovation for ulcerative colitis compared with current treatment options. Because they were still early in development, we were able to model the clinical pathway of three distinct patient populations, exploring different real-world scenarios in advance.
Using an early cost-effectiveness analysis, we identified which patient groups generated the highest monetary valuefor the innovation. These insights gave the client a clear steer on where to focus their product development, helping them prioritize indications and shape a stronger market and investment strategy from the start.
Our work
Our client came to us at a very early stage of their technology development. There were no trial results yet, but they urgently needed clarity: which patient population would benefit most, and would their chosen mode of administration drive up costs or reduce health gains?
We developed an early cost-effectiveness model that translated expert opinion into concrete insights. This allowed the client to see how much better their innovation would need to perform compared to existing options, and to understand the maximum feasible reimbursement level based on expected outcomes.
In short, we turned uncertainty into a clear strategic roadmap for development, positioning, and pricing.
Abraham et al. (2025) Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review. Pharmacoeconomics.
Abraham et al. (2024) Benefits of a digital health technology for elderly nursing home residents. A de-novo cost-effectiveness model of a Digital Health Technology to aid in the assessment of toileting and containment care needs. PLoS ONE.
van Lieshout, Abraham et al. (2024) A cost-utility analysis of cochlear implants for single sided deafness in adults and children in the Netherlands. PLoS ONE.
Abraham et al. (2024) A blueprint for HTA capacity building: Lessons learned from Malta. International Journal of Technology Assessment in Health Care.
Abraham & Franken (2023). A SWOT analysis of the complex interdependencies of the Maltese reimbursement processes. Health Policy OPEN.
A client, already well acquainted with the reimbursement landscape, approached us for a cost-effectiveness analysis of their medical device in the Dutch setting. They were still uncertain which of two patient populations would yield the greatest value, so we evaluated both groups.
Using a cost-effectiveness model fully aligned with Dutch health economic guidelines, we quantified the cost–benefit trade-off for each population. The results gave the client clear, evidence-based guidance on which patient group offered the strongest case for reimbursement, directly informing their strategic positioning and submission strategy.
Scientific work
Our services
Health economic literature review
Reviewing, analysing and reporting of health economic literature relevant to the planning of trials, initial evaluation of the potential health and cost benefit or for selecting a target population.
Support
When short on manpower for building/reviewing economic models, reviewing pharmaco-economic dossiers or for supporting data analysis (max 6 months).
Cost-effectiveness analysis
Advising on & building the appropriate health economic models needed for pricing strategies, reimbursement, and investor readiness based on health economics principles.
Contact HTI
Let’s get in contact to find out the needs to make your innovative health technology a success!
You can fill in the form and I will contact you for a first online call or in-person meeting to find out together what the next steps could be.
Alternatively you can send a message directly to:
